REMARKS/ARGUMENTS

text of the originally presented claims is now amended to distinctly point The out and clearly represent the subject matter of the invention. The word "alleviating" used originally in claim 1 is now replaced by the word "treating" as suggested by the examiner. With the amendment of the text of claim 5 and claims 8-9, original claims 6 and 7 are rendered redundant, and have therefore been canceled. New claim 10 has been added to describe the method of making the isoforskolin composition. Support for this claim is available in the specification.

An appropriate Terminal Disclaimer is filed herewith to overcome the nonstatutory obviousness-type double patenting rejection of claims 1-3 and claims 5-9. Claim 4 is canceled in light of the examiner's comment that there is no support in the specification for the topical use of the composition of the invention in cellulite.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

SABINSA CORPORATION

Dr. Muhammed Majeed Chief Executive Officer

(732) 777 1111

Certificate of Mailing by "Express Mail" "Express Mail" mailing label number ER 697445695 US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service in an envelope addressed to the Commissioner for Patents,

P.O. Box 1450, Alexandria, Virginia 22313-1450,

Broken

Signature of person mailing correspondence

Dr. L. PRAICASH

Typed or printed name of person mailing correspondence